Really you just write so much all over the place so you can look like there's some sort of response to my valid questions about your assumptions, but in reality, there isn't. Slowly written or otherwise.
So here's some new cans opened up from your reply.
Now we are going to abandon the research partnership with Charite, the ones who are involved with orthopaedic indications. Let's abandon Tobias Winkler and his involvement with the development of our current and products and future products.
All so we can set up some sort of a partnership with a manufacturing company to help develop our products. Abandon a world renowned facility to partner with one that may just be looking to get into the drug game. That would make tons of sense.
And I guess now, if we are going to join forces with Lonza in order to build up our production capabilities, building our own prematurely was just a complete waste of money, and even worse, time.
Again, you totally avoided the question of why would Pluristem want to give Lonza the ability to grow MSC'S, the only type they can grow so you say. Why would Lonza want to if Pluristem owns all the rights to grow in 3d bioreactor? Again to grow them for Pluristem.
From day 1, management has boasted about their "in house" manufacturing abilities. Partnering with them just blows that whole statement up. To lease space from Lonza, could possibly be a small possibility. A very far out possibility IMO
But I think if they get a contract that is beyond their production capabilities, there would have an extremely large $ value associated with it. They could just buy their own GMP facility, just like Lonza just did.
So the possibilities you throw out there are riddled with holes and go against what management has wanted to do the whole time, control their own manufacturing abilities. Makes zero sense to me.
